Compare AWF & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWF | DNA |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.3M | 835.7M |
| IPO Year | N/A | 2020 |
| Metric | AWF | DNA |
|---|---|---|
| Price | $9.58 | $9.54 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 461.7K | ★ 2.5M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 7.57% | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.41 | $5.37 |
| 52 Week High | $10.87 | $18.22 |
| Indicator | AWF | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 44.51 |
| Support Level | $9.42 | $9.15 |
| Resistance Level | $9.64 | $10.34 |
| Average True Range (ATR) | 0.08 | 1.59 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 37.50 | 5.65 |
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.